Table 1

Clinical characteristics of the Discovery cohorts

FSIGT cohortsClamp cohorts
BetaGeneTRIPODIRASIRAS-FSHTN-IRMACADNIDDM-Athero
Sample size1,2021251871,034694752182
Age (years)34.6 ± 7.934.8 ± 6.358.8 ± 8.340.6 ± 13.737.4 ± 14.234.5 ± 8.831.8 ± 9.69
Women (%)72.1100.058.359.059.456.758.2
BMI (kg/m2)29.5 ± 6.130.6 ± 5.428.9 ± 5.128.3 ± 5.728.8 ± 5.528.9 ± 5.128.6 ± 6.3
AIRg (μU ⋅ mL−1 min)569 ± 480488 ± 450673 ± 702760 ± 649NANANA
SG (min−1)0.0178 ± 0.00670.0157 ± 0.00410.0208 ± 0.00880.0202 ± 0.0091NANANA
MCRI (L/min)10.1 ± 5.7NA*4.2 ± 2.05.5 ± 2.4NANANA
MCRI (mL ⋅ m−2 ⋅ min−1)NANANANA458.2 ± 111.8471.8 ± 116.3416.2 ± 140.3
SI (×10−4 min−1 ⋅ μU−1 ⋅ mL−1)3.03 ± 1.632.57 ± 1.791.33 ± 1.242.14 ± 1.86NANANA
M (μmol ⋅ m−2 ⋅ min−1)NANANANA1,273 ± 5471,364 ± 6461,255 ± 533
DI1,409 ± 9461,004 ± 7241,245 ± 1,1841,202 ± 1,236NANANA
DI (μmol ⋅ m−2 ⋅ min−1)NANANANANA136.8 ± 100.293.23 ± 54.4
  • Data are mean ± SD unless otherwise indicated. NA, not available.

  • *MCRI is not available for TRIPOD because of the use of tolbutamide in the FSIGT.

  • †DI is not available for HTN-IR because of the lack of 30-min insulin values from oral glucose tolerance testing.